Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.

By E. Hachulla, V. Gressin, L. Guillevin, P. Carpentier, E. Diot, J. Sibilia, A. Kahan, J. Cabane, C. Francès, D. Launay and 6 more. Arthritis & Rheumatism, 2005

780 citations recorded by the source corpus.

Subfields: Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/439ed86097320143656135f29cb201e3768b5f43

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. G. Simonneau

Citations in the corpus

• Diagnosis and assessment of pulmonary arterial hypertension. (2009, background): “The ItinerAIR tudy (57) enrolled 599 patients with scleroderma.”
• Pulmonary arterial hypertension in France: results from a national registry. (2006, background): “Because more than 10% of patients with systemic sclerosis develop PAH, it is recommended that early identification of this complication be obtained by means of a systematic echocardiography-based screening program (9, 24).”
• Updated clinical classification of pulmonary hypertension. (2009, background): “The prevalence of PAH is well established only in scleroderma, and rate of occurrence is estimated between 7% and 12% (29,30).”
• Interstitial lung disease guideline (2008, neutral): “В крупном проспективном исследовании, целью которого был скрининг паци ентов с ССД без значительного поражения легких для выявления ЛАГ, только 6 % из 570 больных име ли ЛАГ по данным допплер ЭхоКГ, и только у (1)/2 ди агноз был подтвержден при катетеризации правых отделов сердца [654].”
• Pulmonary arterial hypertension (2013, methodology): “Prospective studies using echocardiography as a screening method and RHC for confirmation found a prevalence of PAH between 7–12% [24,25].”